Clinical studies have shown that LDRT, as a new adjuvant therapy for pancreatic cancer patients, can increase the ratio of iNOS macrophages to CD8 T cells and reduce tumor vessel diameter (Klug et al. 2013). Here, CD8A is linked to neoplasm.